CDNA - Caredx Inc

NYSE * Health Care * Life Sciences Tools & Services

$17.57

$-0.06 (-0.34%)

About Caredx Inc

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

CDNA Key Statistics

Market Cap

$906.76M

0

P/B Ratio

2.98

EPS

$-0.40

Revenue Growth

+0.3%

Profit Margin

-0.1%

Employees

761

How CDNA Compares to Peers

CDNA has the fastest revenue growth among competitors
CDNA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 1

Margin Rank

#2

of 2

Growth Rank

#1

of 2

Size Rank

#2

of 2

CompanyP/EGrowthCompare
CDNAN/A0%-
AMZN34.60%vs AMZN

Caredx Inc Company Information

Headquarters
California; U.S.A
Website
caredx.com
Sector
Health Care
Industry
Life Sciences Tools & Services
Data Updated:
Ready to invest in CDNA?

Commission-free trading available. Affiliate links.

CDNA Lician Score

10% confidence
5.0/10
Neutral

CDNA has a Lician Score of 5/10 (Average). The stock shows average characteristics across all dimensions.

value

5.0

growth

6.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates CDNAacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

CDNA Financial Snowflake

5-axis analysis across key investment dimensions

5.2/10

Neutral

35810Value5.0Growth6.0Quality5.0Momentum5.0Safety5.05.2/10
5.0

Value

6.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for CDNA